Author

Silvana Hengler

Observed name: S. Hengler

Institution: Immatics Biotechnologies (Germany)

Observed institutions: German Cancer Research Center, Immatics Biotechnologies (Germany)

ORCID: 0000-0001-6973-0800

Observed ORCID: 0000-0001-6973-0800

OpenAlex ID: A5043902981

Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: a phase 1 trial

2025 · Martin Wermke, Dejka M. Araujo, et al. · Nature Medicine · 89

Severe Dysbiosis and Specific Haemophilus and Neisseria Signatures as Hallmarks of the Oropharyngeal Microbiome in Critically Ill Coronavirus Disease 2019 (COVID-19) Patients

2021 · Juliana de Castilhos, Eli Zamir, et al. · Clinical Infectious Diseases · 41

1600O Efficacy and safety of IMA203, a PRAME-directed T-cell receptor (TCR) T-cell therapy, in patients with previously treated advanced or metastatic uveal melanoma from a phase I trial

2025 · S.P. Patel, A.M. Tsimberidou, et al. · Annals of Oncology · 10

Author Correction: Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: a phase 1 trial

2025 · Martin Wermke, Dejka M. Araujo, et al. · Nature Medicine · 9

Patient-level clinical response dynamics in advanced melanoma with anzutresgene autoleucel (anzu-cel), a PRAME-directed T-cell receptor (TCR) T-cell therapy.

2026 · Diwakar Davar, Sapna Pradyuman Patel, et al. · Journal of Clinical Oncology · 2

77MO A phase I trial of IMA203CD8, a PRAME-directed TCR T cell therapy in PRAME-positive solid tumors

2025 · A. Busse, D.M. Araujo, et al. · Immuno-Oncology Technology · 1

Correction to: Severe Dysbiosis and Specific Haemophilus and Neisseria Signatures as Hallmarks of the Oropharyngeal Microbiome in Critically Ill Coronavirus Disease 2019 (COVID-19) Patients

2022 · Juliana de Castilhos, Eli Zamir, et al. · Clinical Infectious Diseases · 1

IMA203CD8 PRAME-directed T-cell Receptor (TCR) T-cell therapy in ovarian cancer: results from a phase 1a study

2026 · Sarah Taylor, Martin Wermke, et al. · Gynecologic Oncology

1704eTiP SUPRAME: A phase III trial evaluating IMA203 T-cell receptor (TCR) T-cell therapy vs investigator’s choice in previously treated advanced cutaneous melanoma

2025 · D. Schadendorf, W. Alsdorf, et al. · Annals of Oncology

Works count: 9

Citation count: 153

H-index: 4

I10-index: 3